All News
#Abs0588 Effectiveness of TNFi vs non-TNFis in obese patients with #rheumatic disease @MilenaGianfran:
👉🏼>16000pts @ACRheum RISE
👉🏼Abatacept➡️larger decreases in CDAI in obese pts
👉🏼Tocilizumab➡️larger decreases in CDAI in non-obese pts
@RheumNow #ACR21
https://t.co/bL5xnG1iNh
Mrinalini Dey DrMiniDey ( View Tweet)
B cell repertoire: the new 🔮?
An algorithm associating baseline CDAI to BCR sequencing outcomes w/
✨Isotypes frequency
✨Somatic Hypermutations
predicts MTX 12mo response w/ 78% sens & spe
#Abstr982 #ACR21 @RheumNow
https://t.co/SZaip6xUaO https://t.co/fbWq34gtzc
Aurelie Najm AurelieRheumo ( View Tweet)
Dusting off the old emergency supply right now (and there’s a lot of dust).
See? It said it on the side of the bottle all this time… they knew.
#ACR21 ABST0957 @RheumNow https://t.co/ygw6BkkjEp https://t.co/DqbIP8uL68
David Liew drdavidliew ( View Tweet)
Does #comorbidity burden affect treatment of #InflammatoryArthritis?
Abs#0577 #ACR21
👉🏼~6500pts; 11 types of IA
👉🏼Higher comorbidity burden➡️more likely to receive steroids than TNFis
👉🏼Are patients w/ IA & multiple comorbidities receiving suboptimal therapy?
@RheumNow #ACRBest https://t.co/iIERb0wL4Y
Mrinalini Dey DrMiniDey ( View Tweet)
Stop by the RheumNow booth! #ACR21 #RheumPix https://t.co/e9dEwkfXU9
Dr. John Cush RheumNow ( View Tweet)
#ACR21 #Abstr0866 Data from #COVID19 GRA Registry showed predictors of poor COVID outcome in 1922 #lupus pts:
Older age
Male
Areas outside Europe, 🇺🇸🇨🇦
Infection <June 2020
Any Corticosteroid dose
Not on therapy
On Rituximab
Comorbidities
⬆️disease activity
@RheumNow #ACRBest https://t.co/u0GF3aDsFA
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Predictors of clinical remission in AS patients Rx with TNFi
⭐️Age and 3-mo BASDAI improvement➡️ predictor of clinical remission criteria
⭐️Normalized ESR and CRP at month 3 were predictors of achievement of BASDAI-CRP
Abst#0931 #ACR21 @RheumNow https://t.co/Ot1ypgNg3A
swethaann23 swethaann23 ( View Tweet)
Had the pleasure of interviewing @MyasoedovaElena from Mayo Clinic on Cognitive Function and RA
#ACR21 @RheumNow
https://t.co/SuXeMhUvk0
Akhil Sood MD AkhilSoodMD ( View Tweet)
In general low health literacy has ⬆️association with non adherence in chronic disease Rx including gout prevention but many other reasons for non adherence cross the health literacy divide. Ex use of alternative Rx, denial, side effects, advice from non HCPs #ACR21 @RheumNow https://t.co/mIIndW1FnV
Janet Pope Janetbirdope ( View Tweet)
Baseline/ Clinical /Imaging predictors of flare when tapering TNFI in axSpA in remission:
⭐️🔼Baseline physician global VAS 🔼flare in 16 weeks after tapering to 2/3 of standard dose.
⭐️🔼Age 🔼flare within 16 weeks after tapering to 1/2 dose
Abst #0929 #ACR21 @RheumNow https://t.co/EFiwKA8z99
swethaann23 swethaann23 ( View Tweet)
My video take on this from yesterday for @RheumNow:
'11 Ways to Stay Away From RA' #ACR21
https://t.co/ELZaL1A20i https://t.co/bynPNibk3q
Links:
David Liew drdavidliew ( View Tweet)
Clinical pearls on Erdheim-Chester disease:
➕"Hairy Kidneys" on CT
➕"Coated" aorta or periaortitis
➕PET scan can confirm diagnosis - affects distal long bones
➕Refer to Oncology for treatment - it's a histiocytic neoplasm!🤓
@RheumNow #ACR21 #MedTwitter https://t.co/MsIqk1rWvE
sheila RHEUMarampa ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @Novartis. All content chosen by #RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
My video take from yesterday for @RheumNow:
'Tired of Doing Nothing About Fatigue' #ACR21
https://t.co/EXjOibL5s9 https://t.co/cR6r8GdDor
Links:
David Liew drdavidliew ( View Tweet)
AxSpA pts who achieve ASDAS low disease activity (LDA) 6 mo after bDMARD initiation
⭐️ 25% achieved ASDAS LDA
⭐️ASDAS LDA achievers were ♂️ + naïve to c/b DMARDs + with PROM / Clinical improvement
⭐️ASDAS LDA non-achievers=depression, uveitis, IBD
Abst# 0925 #ACR21 @RheumNow
swethaann23 swethaann23 ( View Tweet)
Turkish study finds that ETN may be negatively associated w/ the development of ADA in AS pts. Abs 0936 #ACR21 #RheumNow @RheumNow https://t.co/z3pYDpp1NN https://t.co/MR1R41rCHV
Dr. Rachel Tate uptoTate ( View Tweet)
They're VITAL!🤓 Prof @karen_kc123 presents the results of the RCT (huge population size) showing how 5-yr supplementation with Vit D3 &/or n-3 fatty acids ⬇incident autoimmune dse vs. non-takers.
Game changing?!
@RheumNow #ACR21 #ACRBest abs0957 https://t.co/X9QaB1B5Ac
sheila RHEUMarampa ( View Tweet)
PsA impacts many aspects of life. PRO such as VAS pain
and HAQ, are commonly assessed. The FACIT-Fatigue scale, ranked the highest by
patients. Personalized discussion is vital in assessment and shared decision making @RheumNow #ACR21 Abst#0751 https://t.co/gRfYK4sHc6 https://t.co/f5xjUnXsGQ
Dr. Antoni Chan synovialjoints ( View Tweet)
Evaluate effectiveness and Rx survival of different TNFI in cohort of axSpA
⭐️No difference among different TNFI
⭐️No difference between nr-axSpA and AS
⭐️Failure to initial TNFI did not diminish effectiveness or drug survival of subsequent TNFi Rx
Abst#0938 #ACR21 @RheumNow
swethaann23 swethaann23 ( View Tweet)
#ACR21 Abst#0588. TNF vs non-TNFi in obese RA pts
⭐️TNFi use ⬆️ disease activity vs ABA in obese pts
⭐️TNFi use ⬆️ activity vs TCZ in non-obese pts
⭐️No diff w RTX, Tofa
▶️Further research needed: Wt-based dosing? SC vs IV?
https://t.co/K8WycPTgxW @Rheumnow #ACRBest
Links:
Eric Dein ericdeinmd ( View Tweet)